Tredegar Stock

Tredegar EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Tredegar (TG) as of Jul 29, 2026 is 18.32. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 28.21 — a change of -35.05% (lower).

EV/FCF

18.32

YoY

-35.05%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Tredegar is 2026 18.32 . EV/FCF (Enterprise Value to Free Cash Flow) of Tredegar was 2025 28.21 . It decreases by -35.05% lower compared to the previous year.
Access this data via the Eulerpool API

Tredegar Stock analysis

What does Tredegar do? Tredegar Corporation is a multinational corporation based in the USA that operates in various business sectors. The company was founded in 1988 through the merger of Tredegar Industries and Crown Cork International. The company is divided into three main business segments: Plastic Films, Aluminum Extrusions, and Healthcare. Within these segments, Tredegar offers a wide range of products and services for various applications. The Plastic Films product line of Tredegar Corporation includes plastic films used in a variety of applications, including packaging films for food and medical devices, as well as films for the construction, electronics, and automotive industries. Tredegar also produces specialty films for applications that require high chemical resistance or high temperature resistance. Tredegar's Aluminum Extrusions division manufactures aluminum profiles for a variety of applications, including window and door frames, ships, trucks and trailers, as well as solar power systems. They also produce foamed aluminum products that are lightweight yet durable, making them suitable for use in the automotive and construction industries. Tredegar is also active in the healthcare sector and operates a subsidiary called "Nile Therapeutics." Nile develops and markets innovative drug-based therapies for cardiovascular diseases. The company has conducted several clinical trials and is currently in the late stage of developing a new drug called "Cenderitide" for the treatment of acute heart failure. As a global company, Tredegar achieved sales of approximately $1.1 billion in 2020. The company is listed on the New York Stock Exchange and employs around 3,000 employees. Tredegar's products are used in various industries worldwide, and the company has production facilities in North America, Europe, and Asia. Despite already having a wide range of products, the company is constantly making efforts to further develop and diversify its products. Recently, Tredegar announced its entry into the market for medical extrusion components to further expand its healthcare business. Overall, Tredegar is a versatile and expanding company operating in different business sectors and offering a wide range of products. Its strategic focus on innovation and diversification will allow the company to solidify its position globally and generate future growth. Tredegar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tredegar stock

EV/FCF (Enterprise Value to Free Cash Flow) of Tredegar is 18.32 in 2026.

Access this data via the Eulerpool API

Valuation — Tredegar

All Key Metrics — Tredegar